Skip to main content
SpringerLink
Log in

Treatment at Relapse (Surgery and Systemic Treatments)

  • Chapter
  • First Online:
Ovarian Cancers

  • 1049 Accesses

Abstract

Relapses are an important part of epithelial ovarian cancer history due to the natural course of disease and due to inadequate primary treatment. Presently, first relapse means an evolution towards a chronic disease. However, treatments at relapse as chemotherapy, targeted therapy and potentially surgery have substantially prolonged life. So, it is of particular interest to give the patient the best strategy for a better life despite recurrences. Decision making is now mainly based on the expected chemosensitivity of the disease, which was reflected until now by platinum-free interval. This has recently changed. It illustrates biological features of the tumour and host’s profile such as immune and genetics characteristics. Quality of life remains the cornerstone of treatment choice, and benefit-risk balance evaluation should be the main goal for decision.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

Introduction

  1. Harter P, Hilpert F, Mahner S, et al. Prognostic factors for complete debulking in first and second line ovarian cancer. Int J Gynecol Cancer. 2009;19:14–7.

    Article  Google Scholar 

  2. Burger RA, Brady MF, Bookman, MA, et al.; Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011;365(26):2473–83.

    Google Scholar 

  3. Perren TJ, Swart AM, Pfisterer J, et al.; ICON 7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Eng J Med. 2011;365(26):2484–96.

    Google Scholar 

  4. Markman M. Viewing ovarian cancer as a “chronic disease”: what exactly does this mean? Gynecol Oncol. 2006;100:229–30.

    Article  PubMed  Google Scholar 

  5. Hanker L, Loibl S, Buchardi N, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum based therapy. Ann Oncol. 2012;23:2605–12.

    Article  CAS  PubMed  Google Scholar 

  6. Baumann KH, Wagner U, du Bois A. The changing landscape of the therapeutic strategies for recurrent ovarian cancer. Future Oncol. 2012;8:1135–47.

    Article  CAS  PubMed  Google Scholar 

  7. Rustin GJ, van der Burg ME, Griffin CL, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet. 2010;376:1155–63.

    Article  PubMed  Google Scholar 

Platinum Free Interval

  1. Stuart G, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer Intergroup (GCIG) consensus statement on clinicals trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer. 2011;21:750–5.

    Article  PubMed  Google Scholar 

Surgery

  1. Eisenkop SM, Friedman RL, Spirtos NM. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma. Cancer. 2000;88:144–53.

    Article  CAS  PubMed  Google Scholar 

  2. Chi DS, McCaughty K, Diaz JP, et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer. 2006;106:1933–9.

    Article  PubMed  Google Scholar 

  3. Shih KK, Chi DS. Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010;21:75–80.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112:265–74.

    Article  PubMed  Google Scholar 

  5. Zang RY, Harter P, Chi DS, et al. Predictors of survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery based on the pooled analysis of an international collaborative cohort. Br J Cancer. 2011;105:890–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Friedlander M, Trimble E, Tinker A, et al. Clinical trials in recurrent ovarian cancer. Int J Gynecol Cancer. 2011;21:771–5.

    Article  PubMed  Google Scholar 

  7. Harter P, du Bois A, Hahmann M, et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol. 2006;12:1702–10.

    Article  Google Scholar 

  8. Harter P, Sehouli J, Reuss A, et al. Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO study group, NOGGO, AGO- Austria, and MITO. Int J Gynecol Cancer. 2011;21:289–95.

    Article  PubMed  Google Scholar 

Early Relapse

  1. Rose P, Mossbruger K, Fusco N, et al. Gemcitabine reverses cisplatin resistance :demonstration of activity in platinum and multidrug resistant ovarian and peritoneal carcinoma. Gynecol Oncol. 2003;88:17–21.

    Article  CAS  PubMed  Google Scholar 

  2. Sharma R, Graham J, Mitchell H, et al. Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer. 2009;100:707–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Buda A, Floriani I, Rossi R, et al. Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the “Mario Negri” Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R (Istituto Oncologica Romagnolo) group. Br J Cancer. 2004; 90:2112–7.

    Google Scholar 

  4. Gordon A, Fleagle J, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001;19:3312–22.

    CAS  PubMed  Google Scholar 

  5. Ten Bokkel Huinink W, Gore M, Carmichael J, et al. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol. 1997;15:2183–93.

    CAS  PubMed  Google Scholar 

  6. Mutch D, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007;25:2811–8.

    Article  CAS  PubMed  Google Scholar 

  7. Cottu P, Floquet A, Weber B, et al. RPC Saint Paul de Vence: Chimiothérapies (à l’exclusion des thérapies ciblées) et cancer de l’ovaire en rechute. Onko +. 2013;5:33–8.

    Google Scholar 

  8. Pujade Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol. 2014;32:1–8.

    Article  Google Scholar 

  9. Stockler M, Hilpert F, Friedlander M, et al. Patient reported outcome results from the open label phase III AURELIA trial evaluating bevacizumab containing therapy for platinum resistant ovarian cancer. J Clin Oncol. 2014;32:1309–16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Monk BJ, Poveda A, Vergote I, et al. Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double blind, placebo-controlled phase 3 study. Lancet Oncol. 2014;15:799–808.

    Article  CAS  PubMed  Google Scholar 

  11. Pignata S, Lorusso D, Scambia G, et al. Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11); a randomised, open label, phase 2 trial. Lancet Oncol. 2015;16:561–8.

    Article  CAS  PubMed  Google Scholar 

  12. Ledermann JA, Hackshaw A, Kaye S, et al. Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer. J Clin Oncol. 2011;29:3798–804.

    Article  CAS  PubMed  Google Scholar 

  13. Matulonis UA, Berlin S, Ivy P, et al. Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer. J Clin Oncol. 2009;27:5601–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Monk BJ, Poveda A, Vergote I, et al. Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: results from the phase III TRINOVA-1 study. J Clin Oncol. 2015;33(Suppl; abstr 5503).

    Google Scholar 

Late Relapse

  1. Fung-Kee-Fung M, Oliver T, Elit L, et al. Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol. 2007;14:195–208.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO 2.2 trial. Lancet. 2003;361:2099–106.

    Article  CAS  PubMed  Google Scholar 

  3. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer; A Gynecologic Oncology Group Study. J Clin Oncol. 2003;21:3194–200.

    Article  CAS  PubMed  Google Scholar 

  4. du Bois A, Luck HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first line treatment of ovarian cancer. J Natl Cancer Inst. 2003;95:1320–9.

    Article  PubMed  Google Scholar 

  5. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of AGO-OVAR, the NCIC-CTG, and the EORTC GCG. J Clin Oncol. 2006;24:4699–707.

    Article  CAS  PubMed  Google Scholar 

  6. Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum sensitive ovarian cancer in late relapse. J Clin Oncol. 2010;28:3323–9.

    Article  CAS  PubMed  Google Scholar 

  7. Raja FA, Cousell N, Colombo N, et al. Platinum versus platinum combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data. Ann Oncol. 2013;24:3028–34.

    Article  CAS  PubMed  Google Scholar 

  8. Monk BJ, Herzog TJ, Kaye SB, et al. Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010;28:3107–14.

    Article  CAS  PubMed  Google Scholar 

  9. Poveda A, Vergote I, Tjulandin S, et al. Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6–12 months) subpopulation of OVA-301 phase III randomized trial. Ann Oncol. 2011;22:39–48.

    Article  CAS  PubMed  Google Scholar 

  10. Aghajanian C, Blank SV, Goff BA, et al. OCEANS: A randomized double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol. 2012;30(17):2039–45.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Ledermann JA, Embleton AC, Raja F, et al. Cediranib in patients with relapsed platinum-sensitive ovarian cancer (ICON6): a randomised, double blind, placebo-controlled phase 3 trial. Lancet. 2016;387:1066–74.

    Google Scholar 

  12. Liu JF, Barry WT, Birrer M, et al. A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer. Lancet Oncol. 2014;15:1207–14.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Ledermann J, Harter P, Gourley C, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 2014;15:852–61.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. GINECO Group, Institut Bergonié, Bordeaux, France

    Anne Floquet MD

  2. AGO Study Group, Gynecologic Oncology Center, Kiel, Germany

    Jacobus Pfisterer MD, PhD

Authors
  1. Anne Floquet MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jacobus Pfisterer MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jacobus Pfisterer MD, PhD .

Editor information

Editors and Affiliations

  1. AP-HP, Hôtel-Dieu, Paris, France

    Eric Pujade-Lauraine

  2. Centre Léon Bérard, Université Claude Bernard, Lyon, France

    Isabelle Ray-Coquard

  3. Chirurgie cancérologique, HEGP, Paris, France

    Fabrice Lécuru

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Floquet, A., Pfisterer, J. (2017). Treatment at Relapse (Surgery and Systemic Treatments). In: Pujade-Lauraine, E., Ray-Coquard, I., Lécuru, F. (eds) Ovarian Cancers. Springer, Cham. https://doi.org/10.1007/978-3-319-32110-3_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-32110-3_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-32108-0

  • Online ISBN: 978-3-319-32110-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation